Global HER2-Negative Breast Cancer Market 2015-2019


#386516

50pages

Technavio

$ 2500

In Stock

About HER2-negative breast cancer
HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer. HER2-negative breast cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative have a low level of HER2 gene or the HER2 protein. HER2-negative breast cancer can also be HR+ and then the most preferred therapy is hormone therapy. These patients can be treated with chemotherapy or targeted therapy to improve their condition. It can also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine, ixabepilone, and vinorelbine. These drugs have several adverse effects on patients as some of them can attack the healthy cells of the body while destroying the malignant cells.

Technavio's analysts forecast the global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019.

Covered in this report
This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer.

Based on type of drug molecule, the market is segmented as follows:
Biologics
Small molecules
Based on route of administration, the market is segmented as follows:
Oral
Parenteral

This report includes a discussion of the market in the following three regions:
Americas (the US, Canada, Mexico, and Brazil)
EMEA (the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE)
APAC (Japan, China, Australia, Singapore, South Korea, and India)

Technavio's report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
Americas
APAC
EMEA

Key vendors
F. Hoffmann-La Roche
Novartis
Pfizer

Other prominent vendors
AbbVie
AstraZeneca
BioMarin
Bristol-Myers Squibb
Eisai
Eli Lilly
Galena Biopharma
Incyte
Merck
Merck Serono
Merrimack
Nektar
Tesaro

Key market driver
Significant unmet needs
For a full, detailed list, view our report

Key market challenge
Premium-priced therapies
For a full, detailed list, view our report

Key market trend
Emerging therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?